Pfizer, partnered with BioNTech to produce the first coronavirus vaccine to be used in Israel, has warned that there may be gaps in supply until other vaccines begin to be used in large numbers.
Even in Germany, where Pfizer is based, shortages have been reported leading to vaccination centers being closed, The Guardian reports.
Meanwhile, BioNTech CEO Ugur Sahin said that he believes that Pfizer’s vaccine will be effective against the “new” mutant strain of the virus already spreading around the world, although testing has not yet proven this conclusively.
Asked whether that would apply also to a “strong” mutation, Sahin said the vaccine could be “tweaked” as required within six weeks in order to cope with changes in the virus’ structure. However, such tweaks may require new regulatory approval.